AirNexis Therapeutics is a startup based in Israel, most recent round Series A, 2 tracked investors.
Based in Israel, AirNexis Therapeutics is a startup. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
AirNexis Therapeutics is developing a Phase 2 dual PDE3/4 inhibitor (AN01) for the treatment of chronic obstructive pulmonary disease (COPD).
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.